Accéder au contenu
Merck
Toutes les photos(1)

Documents

1446859

USP

Montelukast sodium

United States Pharmacopeia (USP) Reference Standard

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C35H35ClNO3S·Na
Numéro CAS:
151767-02-1
Poids moléculaire :
608.17
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

montelukast

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/C35H36ClNO3S.Na/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29;/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39);/q;+1/p-1/b15-10+;/t32-;/m1./s1

Clé InChI

LBFBRXGCXUHRJY-HKHDRNBDSA-M

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Montelukast sodium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0001433

Montelukast racemate, European Pharmacopoeia (EP) Reference Standard

Y0001435

Montelukast for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001436

Montelukast dicyclohexylamine, European Pharmacopoeia (EP) Reference Standard

Y0001434

Montelukast sodium, European Pharmacopoeia (EP) Reference Standard

1446848

Montelukast racemate, United States Pharmacopeia (USP) Reference Standard

1446815

Montelukast dicyclohexylamine, United States Pharmacopeia (USP) Reference Standard

1446837

Montelukast for peak identification, United States Pharmacopeia (USP) Reference Standard

BP1147

Montelukast dicyclohexylamine, British Pharmacopoeia (BP) Reference Standard

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 10

1 of 10

vibrant-m

D2957000

Domperidone maleate

Fexofenadine hydrochloride United States Pharmacopeia (USP) Reference Standard

USP

1270377

Fexofenadine hydrochloride

Ticlopidine hydrochloride analytical standard, for drug analysis

Supelco

T6654

Ticlopidine hydrochloride

(+)-N-3-Benzyl Nirvanol ≥98% (HPLC), powder

Sigma-Aldrich

B8686

(+)-N-3-Benzyl Nirvanol

α-Naphthoflavone ≥98%

Sigma-Aldrich

N5757

α-Naphthoflavone

USP

USP

1559618

Pregabalin

Caféine European Pharmacopoeia (EP) Reference Standard

Y0000787

Caféine

Caféine phyproof® Reference Substance

PHL89591

Caféine

Ketoconazole 99.0-101.0% (EP, titration)

Sigma-Aldrich

K1003

Ketoconazole

Caféine anhydrous, tested according to Ph. Eur.

Sigma-Aldrich

27602

Caféine

Sheng-Hua Wu et al.
Pediatrics international : official journal of the Japan Pediatric Society, 56(3), 315-322 (2013-12-05)
Previous studies suggested that leukotrienes (LT) were involved in the pathogenesis of Henoch-Schönlein purpura (HSP). This study investigated the efficacy of an add-on therapy with montelukast in the treatment of HSP. In this four-center, double-blind, placebo-controlled, parallel paired comparative study
Yuki Ogawa et al.
European journal of pediatrics, 174(4), 509-518 (2014-09-25)
This study aimed to determine the population pharmacokinetics of doxapram in low-birth-weight (LBW) infants. A total of 92 serum concentration measurements that were obtained from 34 Japanese neonates were analyzed using nonlinear mixed-effect modeling (NONMEM). Estimates generated by NONMEM indicated
Om Prakash Ranjan et al.
Drug delivery, 21(7), 509-518 (2013-11-13)
The purpose of present study was to design, optimize and evaluate osmotically controlled pulsatile release capsule (PRC) of montelukast sodium (MKS) for the prevention of episodic attack of asthma in early morning and associated allergic rhinitis. Assembly of the capsular
Tarek A Ahmed et al.
AAPS PharmSciTech, 15(3), 772-780 (2014-03-22)
The objective of this study was to investigate the sustained release of a hydrophilic drug, montelukast (MK), from two biodegradable polymeric drug delivery systems, in situ implant (ISI) and in situ microparticles (ISM). N-Methyl pyrrolidone (NMP), dimethyl sulfoxide (DMSO), triacetin

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique